Divi's Laboratories, a Rs.3,050 crore plus active pharmaceutical ingredients and intermediates player, has posted impressive financial performance during the second quarter ended September 2015 and its standalone net profit increased by 28.7 per cent to Rs.296 crore from Rs.230 crore in the corresponding period of last year. Its standalone net also improved by 15.9 per cent to Rs.962 crore from Rs.830 crore. The company reported forex gain of Rs.11.66 crore during the quarter under review as against Rs.4.32 in the same period last year.
With improvement in profits, EPS increased to Rs.11.14 from Rs.8.65 in the last period. The company issued bonus share in the ratio of 1:1 during the quarter and its equity capital increased to Rs.53.09 crore from Rs.26.55 crore. Its reserves and surplus stood at Rs.1,048 crore as compared to Rs.3,535 crore.
For the first half ended September 2015, Divi's net sales increased by 20.4 per cent to Rs.1,769 crore from Rs.1,470 crore in the similar period of last year. Its net profit went up by 35.4 per cent to Rs.539 crore from Rs.398 crore. It has capitalized fixed assets aggregating to Rs.146 crore during the current half.